Full Text View
Tabular View
No Study Results Posted
Related Studies
Open Label Pilot Study of Apremilast in Treatment of Rosacea
This study has been completed.
Study NCT01045551   Information provided by Columbia University

First Received on January 7, 2010.   Last Updated on June 10, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Erythematotelangiectatic Rosacea
Papulopustular Rosacea
Additional conditions recognized in this trial
Rosacea
More general conditions related to this trial
Skin Diseases
Interventions listed in this trial
Apremilast
Additional drug interventions recognized in this trial
Thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Julian M. Mackay-Wiggan
Celgene Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services